Xiaofei Wang

List of Publications by Year
in descending order

74 papers	2,855 citations	236925 25 h-index	175258 52 g-index
76 all docs	76 docs citations	76 times ranked	3717 citing authors

#	Article	IF	Citations
1	Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respiratory Medicine,the, 2018, 6, 915-924.	10.7	268
2	Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. Journal of the National Cancer Institute, 2017, 109, .	6.3	236
3	Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial. Journal of Clinical Oncology, 2012, 30, 2063-2069.	1.6	225
4	Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203. Journal of Clinical Oncology, 2008, 26, 848-855.	1.6	186
5	VATS Lobectomy Has Better Perioperative Outcomes Than Open Lobectomy: CALGB 31001, an Ancillary Analysis of CALGB 140202 (Alliance). Annals of Thoracic Surgery, 2015, 99, 399-405.	1.3	170
6	Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 1057-1064.	1.6	159
7	A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307. Journal of Thoracic Oncology, 2010, 5, 1655-1661.	1.1	115
8	Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2018, 105, 924-929.	1.3	97
9	Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. Journal of Clinical Oncology, 2016, 34, 3992-3999.	1.6	87
10	Sublobar Resection for Clinical Stage IA Non—small-cell Lung Cancer in the United States. Clinical Lung Cancer, 2016, 17, 47-55.	2.6	76
11	Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non—Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904. Journal of Clinical Oncology, 2010, 28, 202-206.	1.6	74
12	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non—Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. Journal of Clinical Oncology, 2017, 35, 2885-2892.	1.6	68
13	Immune Activation in Early-Stage Non—Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. Clinical Cancer Research, 2017, 23, 7474-7482.	7.0	65
14	Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 1592-1597.	0.8	64
15	Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer, 2012, 76, 393-396.	2.0	63
16	Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non—Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). Journal of Clinical Oncology, 2017, 35, 2184-2192.	1.6	63
17	Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non—small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 427-436.	0.8	55
18	CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non—Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 214-221.	1.1	49

#	ARTICLE	IF	CITATIONS
19	A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 675-686.e4.	0.8	47
20	Patterns of Distant Metastases After Surgical Management of Non–Small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, e57-e70.	2.6	45
21	Detection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). Journal of Clinical Oncology, 2016, 34, 1484-1491.	1.6	40
22	Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402. Journal of Clinical Oncology, 2009, 27, 4487-4491.	1.6	39
23	The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer. Lung Cancer, 2015, 90, 554-560.	2.0	35
24	Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). International Journal of Radiation Oncology Biology Physics, 2018, 101, 177-185.	0.8	35
25	A Semiparametric Empirical Likelihood Method for Biased Sampling Schemes with Auxiliary Covariates. Biometrics, 2006, 62, 1149-1160.	1.4	30
26	Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clinical Lung Cancer, 2020, 21, 553-561.e1.	2.6	29
27	The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients. Journal of Thoracic Oncology, 2017, 12, 689-696.	1.1	28
28	Sleeve Lobectomy for Non-Small Cell Lung Cancer With N1 Nodal Disease Does Not Compromise Survival. Annals of Thoracic Surgery, 2014, 97, 230-235.	1.3	25
29	Design and Inference for Cancer Biomarker Study with an Outcome and Auxiliary-Dependent Subsampling. Biometrics, 2010, 66, 502-511.	1.4	23
30	Clinical and radiographic predictors of successful therapeutic bronchoscopy for the relief of malignant central airway obstruction. BMC Pulmonary Medicine, 2019, 19, 219.	2.0	22
31	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). Journal of Thoracic Oncology, 2020, 15, 1748-1757.	1.1	21
32	Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma. Journal of Bronchology and Interventional Pulmonology, 2019, 26, 96-101.	1.4	18
33	Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. Journal of Thoracic Oncology, 2018, 13, 1171-1182.	1.1	17
34	Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses. Annals of Translational Medicine, 2019, 7, 244-244.	1.7	17
35	Adjuvant Chemotherapy After Lobectomy for T1–2N0 Non–Small Cell Lung Cancer: Are the Guidelines Supported?. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 755-761.	4.9	16
36	Statistical Considerations for Subgroup Analyses. Journal of Thoracic Oncology, 2021, 16, 375-380.	1.1	16

#	Article	IF	Citations
37	Role of dietary carbohydrates on risk of lung cancer. Lung Cancer, 2021, 155, 87-93.	2.0	16
38	Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?. Translational Lung Cancer Research, 2015, 4, 804-8.	2.8	15
39	Improving Trial Generalizability Using Observational Studies. Biometrics, 2023, 79, 1213-1225.	1.4	15
40	On Enrichment Strategies for Biomarker Stratified Clinical Trials. Journal of Biopharmaceutical Statistics, 2018, 28, 292-308.	0.8	14
41	Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiation Oncology, 2021, 16, 177.	2.7	14
42	Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 298-303.	1.1	13
43	Estimation of AUC or Partial AUC Under Test-Result-Dependent Sampling. Statistics in Biopharmaceutical Research, 2012, 4, 313-323.	0.8	12
44	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist, 2017, 22, 189-198.	3.7	9
45	Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. Lung Cancer, 2020, 141, 14-20.	2.0	9
46	Outcome- and Auxiliary-Dependent Subsampling and Its Statistical Inference. Journal of Biopharmaceutical Statistics, 2009, 19, 1132-1150.	0.8	8
47	Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). Journal of Thoracic Oncology, 2016, 11, 361-369.	1.1	8
48	Radiomics analysis using stability selection supervised component analysis for right-censored survival data. Computers in Biology and Medicine, 2020, 124, 103959.	7.0	8
49	Endpoint surrogacy in oncology Phase 3 randomised controlled trials. British Journal of Cancer, 2020, 123, 333-334.	6.4	8
50	Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. Lung Cancer, 2021, 156, 68-71.	2.0	8
51	A Multi-State Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression. Statistics in Biopharmaceutical Research, 2016, 8, 12-21.	0.8	7
52	ROC curve estimation under test-result-dependent sampling. Biostatistics, 2013, 14, 160-172.	1.5	6
53	Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer, 2015, 90, 281-287.	2.0	6
54	Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy. Technology in Cancer Research and Treatment, 2019, 18, 153303381984907.	1.9	6

#	Article	IF	Citations
55	Clinical prognostic model for older patients with advanced non-small cell lung cancer. Journal of Geriatric Oncology, 2019, 10, 555-559.	1.0	6
56	Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729). Oncologist, 2021, 26, e435-e444.	3.7	5
57	Targeted Clinical Trials. , 2012, , 157-177.		5
58	Bias-adjusted Kaplan–Meier survival curves for marginal treatment effect in observational studies. Journal of Biopharmaceutical Statistics, 2019, 29, 592-605.	0.8	4
59	Definitive Radiotherapy for Inoperable Stage IIB Non–small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness. Clinical Lung Cancer, 2020, 21, 238-246.	2.6	4
60	Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes. Lung Cancer, 2022, 166, 27-39.	2.0	4
61	Auxiliary variable–enriched biomarker–stratified design. Statistics in Medicine, 2018, 37, 4610-4635.	1.6	3
62	Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. JAMA Network Open, 2020, 3, e2014661.	5.9	3
63	Predictive accuracy of markers or risk scores for interval censored survival data. Statistics in Medicine, 2020, 39, 2437-2446.	1.6	3
64	Latent Profile/Class Analysis Identifying Differentiated Intervention Effects. Nursing Research, 2022, 71, 394-403.	1.7	3
65	Time–dependent classification accuracy curve under marker–dependent sampling. Biometrical Journal, 2016, 58, 974-992.	1.0	2
66	Sample size calculation for studies with grouped survival data. Statistics in Medicine, 2018, 37, 3904-3917.	1.6	2
67	Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment. Journal of Biopharmaceutical Statistics, 2020, 30, 1060-1076.	0.8	2
68	Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2022, 23, 177-184.	2.6	2
69	Statistical aspect of translational and correlative studies in clinical trials. Chinese Clinical Oncology, 2016, 5, 11.	1.2	1
70	Nonparametric Modeling Auxiliary Covariates in Random Coefficient Models. Communications in Statistics Part B: Simulation and Computation, 2012, 41, 1271-1281.	1.2	0
71	Risk calculators are useful but…. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 706-707.	0.8	0
72	Reply to T.-H. Wang et al. Journal of Clinical Oncology, 2017, 35, 118-120.	1.6	0

#	Article	IF	Citations
73	Statistical issues and advances in cancer precision medicine research. Journal of Biopharmaceutical Statistics, 2018, 28, 215-216.	0.8	0
74	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. JTO Clinical and Research Reports, 2021, 2, 100208.	1.1	0